This Friday August 6, the Haute autorité de santé (HAS) announced immunocompromised people will be able to get a preventive Covid-19 therapy based on monoclonal antibodies. The latter are more likely to develop severe coronavirus and are not effectively protected by the vaccine. Their immune systems being unable to fully respond to Covid vaccines, it is recommended to give them three doses, and for many of them, this is not enough.
According to the HAS, this therapy will apply to “about 130,000 people in France”, like those given an organ transplant and under anti-rejection immunosuppressive therapy, as well as those suffering from chronic dialyses, or patients suffering from some cancers and inflammatory autoimmune diseases.
The “Ronapreve” therapy now enjoys an early authorization for this special group, a process enabling to give a medication before its issuance authorization is issued. And the Agence Nationale de Sécurité du Médicament (National Medicines Safety Agency – ANSM) has assessed the presumed benefit-risk ratio. Yet, during this granted period of time as for giving this preventive therapy, the Haute Autorité de Santé shall study the effectiveness of the therapy and see - depending on new antibodies soon to be marketed - which therapy enables the best protection over time.
Developed by American company Regeneron, in partnership with Roche laboratory, this therapy combines two monoclonal antibodies directed against Covid’s spike protein. Antibodies prevent the virus from penetrating the cells and fight against its multiplication. The latter will have to do the work antibodies of immunocompromised people cannot do, and protect them from severe infection.
Covid: vaccines and therapies available or still being reviewed
Take a stock on Covid-19 vaccines and treatments across the world. Where are the first vaccines at? Are there effective Covid-19 treatments? What are the latest discoveries and breakthroughs performed by scientists? [Read more]
This Wednesday July 28, the European Union announced they have secured a deal for a new experimental coronavirus therapy, Sotrovimab, developed by UK laboratory GSK. A promising monoclonal antibody therapy. [Read more]
As Covid variants keep on spreading across the world, Eli Lilly laboratories has seen their approval removed for marketing bamlanivimab, as a monotherapy, being a therapy based on monoclonal antibodies. Why? Its effectiveness challenged by new coronavirus strains. Keep reading to find out more! [Read more]
This Monday March 15, the Agence du Médicament (French Medicines Agency) announced that two monoclonal antibody therapies, namely REGN-COV2 and Eli Lilly laboratory's therapy based on bamlanivimab and etesevimab were now approved in France. [Read more]
As the race for Covid vaccines and therapies is speeding up all over the world, drugmaker Eli Lilly announced this Wednesday March 10 their antibody therapy mixing Bamlanivimab and Etsesevimab is said to reduced by 87% hospitalization and death risk in the event of severe infection. A combined therapy that received emergency use authorization back to late February from the Food & Drug Administration. [Read more]
Official website
www.has-sante.fr
Covid: vaccines and therapies available or still being reviewed
Coronavirus: The European Union ordered a new antibody therapy
Covid: effectiveness of monoclonal antibodies challenged by variants
Covid: Eli Lilly antibody therapy said to reduce hospitalization risks, a study finds
